Disease · MONDO_0020804

basal cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. basal cell carcinoma. Diseases, record MONDO_0020804. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020804

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: basal cell carcinoma; Open Targets
Open Targets ID: MONDO_0020804; Open Targets
Other names: basal cell cancer, epithelioma, basal cell, malignant basal cell neoplasm; Open Targets
MeSH: D002280; MeSH
NCI Thesaurus: C156767; NCI Thesaurus
NCI Thesaurus: C7586; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 57 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs57

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
VISMODEGIB	CHEMBL473417	Small molecule	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs and TTD	30	27	27	Drugs and targets
IMIQUIMOD	CHEMBL1282	Small molecule	Approval	DailyMed and EMA Human Drugs	16	13	13	Drugs and targets
SONIDEGIB	CHEMBL2105737	Small molecule	Approval	EMA Human Drugs	13	12	12	Drugs and targets
CEMIPLIMAB	CHEMBL4297723	Antibody	Approval	DailyMed	8	7	7	Drugs and targets
AMINOLEVULINIC ACID HYDROCHLORIDE	CHEMBL1200582	Small molecule	Approval	EMA Human Drugs	5	4	2	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
SONIDEGIB PHOSPHATE	CHEMBL3137317	Small molecule	Approval	DailyMed and FDA	2	0	0	Drugs and targets
AMINOLEVULINIC ACID	CHEMBL601	Small molecule	Phase 3	ClinicalTrials.gov	10	10	8	Drugs and targets
METHYL AMINOLEVULINATE	CHEMBL1096562	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
PATIDEGIB	CHEMBL538867	Small molecule	Phase 3	ClinicalTrials.gov	6	4	4	Drugs and targets

1 to 10 of 57

See all 57 drugs

Targets66

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SMO	Protein smoothened	4	Smoothened homolog antagonist; Smoothened homolog inhibitor	Approval	https://conductscience.org/library/genes/6608	Drugs and targets
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
VDR	Vitamin D3 receptor	3	Vitamin D receptor agonist	Phase 2/3	https://conductscience.org/library/genes/7421	Drugs and targets
LAG3	Lymphocyte activation gene 3 protein	2	Lymphocyte activation gene 3 protein inhibitor	Phase 2	https://conductscience.org/library/genes/3902	Drugs and targets
TLR7	Toll-like receptor 7	2	Toll-like receptor 7 agonist	Approval	https://conductscience.org/library/genes/51284	Drugs and targets
CD40	Tumor necrosis factor receptor superfamily member 5	1	Tumor necrosis factor receptor superfamily member 5 agonist	Phase 1	https://conductscience.org/library/genes/958	Drugs and targets
CSNK2A1	Casein kinase II subunit alpha	1	Casein kinase II alpha inhibitor	Phase 1	https://conductscience.org/library/genes/1457	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	1	Vascular endothelial growth factor receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/2321	Drugs and targets

1 to 10 of 66

See all 66 targets

Trials126

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01367665	STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma	Phase 2	1,232	2019-06-06	Basal Cell Carcinoma	VISMODEGIB	Its record names the disease	ClinicalTrials.gov
NCT02144077	Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy	Phase 3	281	2019-03-11	Basal Cell Carcinoma (BCC)	AMINOLEVULINIC ACID, METHYL AMINOLEVULINATE	Its record names the disease	ClinicalTrials.gov
NCT01327053	A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma	Phase 2	230	2015-11-23	Basal Cell Carcinoma	SONIDEGIB	Its record names the disease	ClinicalTrials.gov
NCT01815840	A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas	Phase 2	229	2016-08-04	Basal Cell Carcinoma	VISMODEGIB	Its record names the disease	ClinicalTrials.gov
NCT03573401	Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).	Phase 3	187	2025-04-29	Superficial Basal Cell Carcinoma	AMINOLEVULINIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00604890	Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma	Phase 1/2	186	2019-03-05	Superficial Basal Cell Carcinoma	UBIDECARENONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00002975	Photodynamic Therapy in Treating Patients With Skin Cancer	Phase 2	180	2013-10-10	Non-melanomatous Skin Cancer, Precancerous Condition	AMINOLEVULINIC ACID	Its record names the disease	ClinicalTrials.gov
NCT03703310	Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)	Phase 3	174	2024-07-03	Basal Cell Nevus Syndrome	PATIDEGIB	Its record names the disease	ClinicalTrials.gov
NCT00189306	Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream	Phase 3	169	2008-11-26	Superficial Basal Cell Carcinoma	IMIQUIMOD	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03132636	PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy	Phase 2	138	2022-07-26	Carcinoma, Basal Cell	CEMIPLIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 126

See all 126 trials

Comparisons in its trials39

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vismodegib - Locally Advanced vs Vismodegib - Metastatic: deaths from any cause	103 of 1,119	19 of 96	1,215	NCT01367665	Trial comparisons
Vismodegib - Locally Advanced vs Vismodegib - Metastatic: serious adverse events	272 of 1,119	31 of 96	1,215	NCT01367665	Trial comparisons
BF-200 ALA vs Methyl-aminolevulinate: deaths from any cause	0 of 138	1 of 143	281	NCT02144077	Trial comparisons
BF-200 ALA vs Methyl-aminolevulinate: serious adverse events	3 of 138	7 of 143	281	NCT02144077	Trial comparisons
LDE225 200 mg qd vs LDE225 800 mg qd: deaths from any cause	1 of 79	7 of 150	229	NCT01327053	Trial comparisons
LDE225 200 mg qd vs LDE225 800 mg qd: serious adverse events	16 of 79	58 of 150	229	NCT01327053	Trial comparisons
Vismodegib Intermittent Schedule vs Vismodegib Induction Followed by Intermittent Schedule: serious adverse events	24 of 114	23 of 113	227	NCT01815840	Trial comparisons
BF-200 ALA vs Vehicle: deaths from any cause	0 of 145	0 of 42	187	NCT03573401	Trial comparisons
BF-200 ALA vs Vehicle: serious adverse events	3 of 145	2 of 42	187	NCT03573401	Trial comparisons
Patidegib Topical Gel, 2%, vs Patidegib Topical Gel, Vehicle: deaths from any cause	0 of 87	0 of 87	174	NCT03703310	Trial comparisons

1 to 10 of 39

See all 39 comparisons in its trials

Papers from its trials70

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39400600	RESULT	1	PubMed
36297594	RESULT	1	PubMed
33997740	RESULT	1	PubMed
29432644	RESULT	1	PubMed
29175429	RESULT	1	PubMed
27932240	RESULT	2	PubMed
27838224	RESULT	1	PubMed
26546616	RESULT	1	PubMed
26239203	RESULT	1	PubMed
24929884	RESULT	1	PubMed

1 to 10 of 70

See all 70 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0020804

GET https://conductscience.org/api/diseases/v1/MONDO_0020804/drugs?page=2

API reference For AI assistants